@article{article, title = {{DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)鈥擜 randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps5103 }}, year = {{2022}}, month = {{6}}, author = {{Niazi T and McBride SM and Williams S and Davis ID and Stockler MR and Martin AJ and Bracken K and Roncolato F and Horvath L and Sengupta S and Martin J et al}}, doi = {{10.1200/jco.2022.40.16_suppl.tps5103}}, volume = {{40}}, journal = {{Journal of Clinical Oncology}}, issue = {{16_suppl}}, pages = {{TPS5103-TPS5103}}, note = {{Accessed on 2025/07/13}}}